一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒S蛋白单区域亚单位纳米疫苗
本发明公开了一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒S蛋白单区域区域亚单位纳米疫苗。本发明以病毒的受体结合域(Receptor binding domain,RBD)作为抗原，并与幽门螺旋杆菌多聚物蛋白(HP_Ferritin)连接组成融和蛋白RBD‑HP_Ferritin，实现抗原多聚化；再利用真核细胞表达系统表达，可通过HP_Ferritin自组装作用形成二十四聚体纳米抗原。该方案可克服RBD单体免疫原性不足的缺点，所得疫苗能显著的提高宿主针对病毒的中和抗体的水平，产生的抗体具有强力阻挡病毒入侵靶细胞的能力。而且本发明疫苗制备方法简单、易于纯化，安全性高，疫苗可较快的应用于临床试验。.
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Europäisches Patentamt - (2021) vom: 09. Juli Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Chinesisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2021-07-09, Last update posted on www.tib.eu: 2023-07-01, Last updated: 2023-07-08 |
|---|
| Patentnummer: |
CN111560074 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA005747015 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA005747015 | ||
| 003 | DE-627 | ||
| 005 | 20230708160317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210531s2021 xx |||||o 00| ||chi c | ||
| 035 | |a (DE-627)EPA005747015 | ||
| 035 | |a (EPA)CN111560074 | ||
| 035 | |a (EPA)72068927 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 245 | 1 | 0 | |a 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒S蛋白单区域亚单位纳米疫苗 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2021-07-09, Last update posted on www.tib.eu: 2023-07-01, Last updated: 2023-07-08 | ||
| 520 | |a 本发明公开了一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒S蛋白单区域区域亚单位纳米疫苗。本发明以病毒的受体结合域(Receptor binding domain,RBD)作为抗原，并与幽门螺旋杆菌多聚物蛋白(HP_Ferritin)连接组成融和蛋白RBD‑HP_Ferritin，实现抗原多聚化；再利用真核细胞表达系统表达，可通过HP_Ferritin自组装作用形成二十四聚体纳米抗原。该方案可克服RBD单体免疫原性不足的缺点，所得疫苗能显著的提高宿主针对病毒的中和抗体的水平，产生的抗体具有强力阻挡病毒入侵靶细胞的能力。而且本发明疫苗制备方法简单、易于纯化，安全性高，疫苗可较快的应用于临床试验。 | ||
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a bio | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2021) vom: 09. Juli |
| 773 | 1 | 8 | |g year:2021 |g day:09 |g month:07 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/72068927/publication/CN111560074A1?q=CN111560074 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2021 |b 09 |c 07 |
| 951 | |a AR | ||
| 952 | |j 2021 |b 09 |c 07 | ||